AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1735345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times a day for 30 days)
Number of subjects: 65
Study 1735345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 6715083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg metildigoxin (Lanitop)
Number of subjects: 24
Study 6715083 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg beta‐acetyldigoxin (Novodigal)
Number of subjects: 24
Study 30759183 — intervention group
Group type: EXPERIMENTAL
Intervention: r-aP + Td
Number of subjects: 62
Study 30759183 — intervention group
Group type: COMPARATOR
Intervention: cd/Tdap
Number of subjects: 62
Study 30581203 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 198
Study 30581203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 30581203 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV‐1 infection
Number of subjects: 198
Study 30581203 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV‐1 seropositive participants
Number of subjects: 198
Study 27809956 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists' assessments
Number of subjects: 155
Study 27809956 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologists' assessments
Number of subjects: 155
Study 27809956 — intervention group
Group type: COMPARATOR
Intervention: Cost of assessment by ophthalmologists
Number of subjects: 155
Study 27809956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of assessment by optometrists
Number of subjects: 155
Study 27809956 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists' decision-making
Number of subjects: 155
Study 24521088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alters related to the participant
Number of subjects: 270
Study 24521088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alters who did not use drugs
Number of subjects: 270
Study 24521088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alters embedded in smaller networks
Number of subjects: 270
Study 24521088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alters with more frequent contact with the participant
Number of subjects: 270
Study 24521088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alters' drinking history
Number of subjects: 270
Study 24521088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alters' criminal history
Number of subjects: 270
Study 22194637 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine
Number of subjects: 67
Study 22194637 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 67
Study 20657257 — intervention group
Group type: EXPERIMENTAL
Intervention: BBS (antibiotic-impregnated bioabsorbable bone substitute)
Number of subjects: 30
Study 20657257 — intervention group
Group type: COMPARATOR
Intervention: PMMA (antibiotic-impregnated polymethylmethacrylate cement beads)
Number of subjects: 30
Study 17482880 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated-dose CFRT
Number of subjects: 843
Study 17482880 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CFRT
Number of subjects: 843
Study 14600809 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 49
Study 14600809 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 49
Study 12085202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by tamoxifen
Number of subjects: 98
Study 12085202 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy followed by tamoxifen
Number of subjects: 98
Study 12085202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 98
Study 8594675 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 39
Study 8594675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme‐linked immunosorbent assay (ELISA)
Number of subjects: 39
Study 8594675 — intervention group
Group type: COMPARATOR
Intervention: Microscopy of tissue smears
Number of subjects: 39
Study 2765262 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8 fish containing meals per week for 12 weeks
Number of subjects: 100
Study 2765262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 fish containing meals per week
Number of subjects: 100
Study 2765262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 fish containing meals per week
Number of subjects: 100
Study 2765262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 1170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 128
Study 1170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 128
Study 1170 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital 50 mg
Number of subjects: 128
Study 1170 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital 100 mg
Number of subjects: 128
Study 31278109 — intervention group
Group type: EXPERIMENTAL
Intervention: Homestead Food Production (HFP) programme
Number of subjects: 2700
Study 31278109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2700
Study 29017493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 200
Study 29017493 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone
Number of subjects: 200
Study 26549586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PEG-asparaginase (15 doses of 2500 IU/m² every 2 weeks)
Number of subjects: 463
Study 26549586 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular native E coli L-asparaginase (30 doses of 25,000 IU/m² weekly)
Number of subjects: 463
Study 26549586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PEG-asparaginase
Number of subjects: 463
Study 26549586 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular native E coli L-asparaginase
Number of subjects: 463
Study 23782890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer registry‐contacted colorectal cancer (CRC) cases who agreed to study contact
Number of subjects: 0
Study 23782890 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk relatives contacted for intervention participation
Number of subjects: 0
Study 23782890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer registry source
Number of subjects: 0
Study 20733274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.06 mg/kg/day) with Growth Hormone (GH 0.35 mg/kg/week)
Number of subjects: 76
Study 20733274 — intervention group
Group type: COMPARATOR
Intervention: Growth Hormone (GH 0.35 mg/kg/week) with Placebo (Pl)
Number of subjects: 76
Study 19339393 — intervention group
Group type: EXPERIMENTAL
Intervention: Putative cancer prevention diet
Number of subjects: 896
Study 19339393 — intervention group
Group type: COMPARATOR
Intervention: Diet of 5 servings of vegetables and fruit daily (Control)
Number of subjects: 896
Study 16961610 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) added to ASA-PRP
Number of subjects: 66
Study 16961610 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 66
Study 16961610 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 66
Study 12818944 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid isobaric lidocaine 30 mg
Number of subjects: 59
Study 12818944 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid hyperbaric bupivacaine 5.25 mg
Number of subjects: 59
Study 10890135 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg mefloquine administered on days 0, 1, 7, 14, 21 and 28; further 5 weekly doses of 250 mg mefloquine.
Number of subjects: 12
Study 10890135 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg mefloquine administered as further 5 weekly doses.
Number of subjects: 12
Study 10890135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (both dosages)
Number of subjects: 12
Study 8851688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg iv at 0 min)
Number of subjects: 6
Study 8851688 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg po at -60 min)
Number of subjects: 6
Study 8851688 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.08 mg/kg po at -60 min)
Number of subjects: 6
Study 1635441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator
Number of subjects: 40
Study 1635441 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 40
Study 1635441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6369532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (0.5 g every 6 h for 4 days)
Number of subjects: 569
Study 6369532 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g every 12 h for 2 days)
Number of subjects: 569
Study 31504495 — intervention group
Group type: EXPERIMENTAL
Intervention: Local coalitions promoting smoke-free policies/enforcement
Number of subjects: 28
Study 31504495 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 30977736 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS smartphone intervention for 12 weeks
Number of subjects: 82
Study 28545934 — intervention group
Group type: EXPERIMENTAL
Intervention: Weibull cure‐mixture model
Number of subjects: 0
Study 28545934 — intervention group
Group type: COMPARATOR
Intervention: Standard Weibull model
Number of subjects: 0
Study 28545934 — intervention group
Group type: COMPARATOR
Intervention: Nonparametric model based on Bayesian bootstrap
Number of subjects: 0
Study 26137975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (150 mg subcutaneous injections once weekly for 25 weeks)
Number of subjects: 27
Study 26137975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 26137975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept and Rituximab
Number of subjects: 27
Study 26137975 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Rituximab
Number of subjects: 27
Study 22796109 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (dronabinol)
Number of subjects: 29
Study 22796109 — intervention group
Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 29
Study 20739631 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPE-V
Number of subjects: 59
Study 20739631 — intervention group
Group type: COMPARATOR
Intervention: GRBAS
Number of subjects: 59
Study 18975334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 5 mg orally, once daily
Number of subjects: 30
Study 18975334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiresorptive treatment)
Number of subjects: 30
Study 16871061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feedback
Number of subjects: 42
Study 16871061 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape-assisted oral feedback
Number of subjects: 42
Study 16871061 — intervention group
Group type: COMPARATOR
Intervention: Control (no debriefing)
Number of subjects: 42
Study 12661887 — intervention group
Group type: EXPERIMENTAL
Intervention: PeaceBuilders Intervention (PBI)
Number of subjects: 4000
Study 12661887 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention (PBD)
Number of subjects: 4000
Study 11783101 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CDDP)
Number of subjects: 100
Study 11783101 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 100
Study 9365765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumagillin
Number of subjects: 60
Study 9365765 — intervention group
Group type: COMPARATOR
Intervention: Other drug regimens (albendazole plus metronidazole, sulphadiazine plus pyrimethamine, atovaquone, doxycycline plus nifuroxazide, itraconazole, flubendazole, chloroquine, paromomycin, sparfloxacin)
Number of subjects: 60
Study 8498397 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended introduction to CAGE questions
Number of subjects: 43
Study 8498397 — intervention group
Group type: COMPARATOR
Intervention: Closed-ended introduction to CAGE questions
Number of subjects: 43
Study 3305212 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC UKALL VIII
Number of subjects: 0
Study 3305212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained chemotherapy
Number of subjects: 0
Study 3305212 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-centre therapy
Number of subjects: 0
Study 29305129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based vegetable gardening intervention delivered by cooperative extension master gardeners, including guidance to establish three seasonal vegetable gardens, with provided plants, seeds, and gardening supplies.
Number of subjects: 46
Study 29305129 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control arm (no intervention).
Number of subjects: 46
Study 27613456 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 169
Study 27613456 — intervention group
Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 169
Study 25175842 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (100 mg)
Number of subjects: 150
Study 25175842 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ropivacaine (37.5 mg)
Number of subjects: 150
Study 25175842 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 150
Study 23050696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (Lac) at 2 g/kg diet
Number of subjects: 5
Study 23050696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrated sodium calcium aluminosilicate (HSCAS) at 2 g/kg diet
Number of subjects: 5
Study 23050696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannan oligosaccharides (MOS) at 2 g/kg diet
Number of subjects: 5
Study 23050696 — intervention group
Group type: COMPARATOR
Intervention: Aflatoxin (AF) at 200 ppb
Number of subjects: 5
Study 21556992 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LAP)
Number of subjects: 105
Study 21556992 — intervention group
Group type: COMPARATOR
Intervention: Open sigmoid resection (OP)
Number of subjects: 105
Study 18300872 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 842
Study 18300872 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 842
Study 18300872 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 842
Study 18300872 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 842
Study 16547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: 2 g/kg/day of protein equivalent
Number of subjects: 25
Study 16547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B: 1.2 g/kg/day protein equivalent
Number of subjects: 25
Study 12535038 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg.kg‐1 magnesium in 30 ml 0.9% NaCl over 20 min
Number of subjects: 40
Study 12535038 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl alone in the same volume
Number of subjects: 40
Study 10952794 — intervention group
Group type: COMPARATOR
Intervention: Subclavian catheter
Number of subjects: 102
Study 10952794 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC line
Number of subjects: 102
Study 9196419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold intermittent blood cardioplegia (CBC) with moderate hypothermic cardiopulmonary bypass
Number of subjects: 20
Study 9196419 — intervention group
Group type: COMPARATOR
Intervention: Warm continuous blood cardioplegia (WBC) with mild hypothermic cardiopulmonary bypass
Number of subjects: 20
Study 7950448 — intervention group
Group type: EXPERIMENTAL
Intervention: Berodual
Number of subjects: 40
Study 7950448 — intervention group
Group type: COMPARATOR
Intervention: Atrovent
Number of subjects: 40
Study 3552020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HC) 400 mg daily for the first month, then 200 mg daily thereafter
Number of subjects: 28
Study 3552020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28960254 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 0.25%
Number of subjects: 327
Study 28960254 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 0.5%
Number of subjects: 327
Study 28960254 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 1%
Number of subjects: 327
Study 28960254 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE-052 ointment at 3%
Number of subjects: 327
Study 28960254 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 327
Study 28960254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 327
Study 29071930 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion treatment
Number of subjects: 66
Study 29071930 — intervention group
Group type: COMPARATOR
Intervention: Herbal medicine (Yupingfeng Granules)
Number of subjects: 66
Study 29071930 — intervention group
Group type: COMPARATOR
Intervention: Both groups (moxibustion and control)
Number of subjects: 66
Study 29071930 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion vs Herbal medicine
Number of subjects: 66
Study 24958525 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with long-chain omega-3 polyunsaturated fatty acids (EPA and DHA) for 16 weeks
Number of subjects: 95
Study 24958525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 22813395 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture removal instructions and equipment
Number of subjects: 183
Study 22813395 — intervention group
Group type: COMPARATOR
Intervention: Standard advice and follow-up care
Number of subjects: 183
Study 15820324 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 80
Study 15820324 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated condition
Number of subjects: 80
Study 15820324 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated condition
Number of subjects: 80
Study 12242598 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton powder 0.5 g
Number of subjects: 16
Study 12242598 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton powder 1 g
Number of subjects: 16
Study 12242598 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton powder 2 g
Number of subjects: 16
Study 12242598 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton powder 4 g
Number of subjects: 16
Study 12242598 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton powder (all doses)
Number of subjects: 16
Study 9640122 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Number of subjects: 40
Study 9640122 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 40
Study 7652030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dose (15 micrograms/kg, approx. 1.1 mg for average subject)
Number of subjects: 38
Study 7652030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2761122 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (E) 0.2 g.kg‐1 body wt
Number of subjects: 6
Study 2761122 — intervention group
Group type: COMPARATOR
Intervention: Starch (C)
Number of subjects: 6
Study 2761122 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (E)
Number of subjects: 6
Study 326642 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (6 mg daily)
Number of subjects: 21
Study 326642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29685161 — intervention group
Group type: EXPERIMENTAL
Intervention: Novaloc attachment system
Number of subjects: 26
Study 29685161 — intervention group
Group type: COMPARATOR
Intervention: Locator attachment system
Number of subjects: 26
Study 27956829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with supportive phone calls during home exercise bicycle training
Number of subjects: 53
Study 27956829 — intervention group
Group type: COMPARATOR
Intervention: Control phase (training without phone calls)
Number of subjects: 53
Study 27956829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with supportive phone calls
Number of subjects: 53
Study 24754137 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire fixation with ligaments repaired (Group A)
Number of subjects: 127
Study 24754137 — intervention group
Group type: COMPARATOR
Intervention: Hook-plate fixation without ligaments repaired (Group B)
Number of subjects: 127
Study 21975451 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow amplitude modulations (AM) at rates of 1.5, 3.5, 7.5, 15.5, and 31.5 Hz
Number of subjects: 14
Study 21975451 — intervention group
Group type: EXPERIMENTAL
Intervention: Four types of carrier: pure tone and 1/3‐, 2‐, and 5‐octave pink noise
Number of subjects: 14
Study 21975451 — intervention group
Group type: EXPERIMENTAL
Intervention: Globally synchronized activity in the human auditory cortex
Number of subjects: 14
Study 20435239 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/dexmedetomidine
Number of subjects: 18
Study 20435239 — intervention group
Group type: COMPARATOR
Intervention: Propofol/ketamine
Number of subjects: 18
Study 20435239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 18307460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day)
Number of subjects: 70
Study 18307460 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study 16120227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 0 (smoking men)
Number of subjects: 22044
Study 16120227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 (smoking men)
Number of subjects: 22044
Study 16120227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 (smoking men)
Number of subjects: 22044
Study 16120227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 (smoking women)
Number of subjects: 22044
Study 12153835 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient commitment
Number of subjects: 184
Study 12153835 — intervention group
Group type: COMPARATOR
Intervention: Released without outpatient commitment
Number of subjects: 184